SIRT6 Gene Therapy Rolls Back Aging Clock in Senior Dogs
Genflow's centenarian-derived SIRT6c therapy lowered biological age in aged beagles with early muscle preservation signals, though results remain preliminary.
Summary
Genflow Biosciences has shared interim results from its SLAB trial, testing a SIRT6 gene variant derived from centenarians in 24 beagles over age ten. By day 182, dogs receiving the plasmid DNA therapy showed DNA methylation age reductions of up to 1.08 years compared to 0.07 years in controls. Preliminary muscle tissue analysis also showed preservation of fast-twitch type II muscle fibers and increased regenerative satellite cells. However, no results yet reach statistical significance, frailty scores did not separate from controls, and the primary endpoint at day 320 is still pending. The therapy was well tolerated. While these are early signals rather than confirmed findings, the study raises the promising question of whether targeting aging biology late in life — in dogs or eventually humans — can meaningfully alter the aging trajectory.
Detailed Summary
Genflow Biosciences presented interim findings from its SLAB (Sarcopenia and Longevity in Aged Beagles) study at the Animal Longevity Summit 2026 in Toronto, offering an early look at whether a centenarian-derived SIRT6 gene variant can influence biological aging in already-old animals. The study is important because it tests a translational question: can an aging intervention still work when started late in life, rather than prophylactically?
The trial enrolled 24 beagles over age ten in a randomized, blinded, controlled design with four arms — vehicle control, low-dose plasmid DNA, high-dose plasmid DNA, and an AAV8 SIRT6c benchmark group. At day 182, the Horvath dog DNA methylation clock recorded mean biological age reductions of 1.08 years in the low-dose group and 0.48 years in the high-dose group, versus just 0.07 years in controls. Ten of 12 treated dogs showed a biological age decline. Despite these directional signals, no between-group difference reached statistical significance, with p-values ranging from 0.31 to 0.80.
Skeletal muscle histology added a complementary layer. Treated dogs showed preservation of type II muscle fibers — the fast-twitch fibers most vulnerable to age-related sarcopenia — along with increased density of Pax7-positive satellite cells, which drive muscle regeneration. The strongest histological effects appeared in the high-dose pDNA and AAV8 groups, though this ranking diverged from the methylation clock results, suggesting the readouts may capture distinct biological processes.
The trial has been extended, with the primary confirmatory methylation endpoint now moved to day 320. Frailty scores and other functional measures did not yet separate meaningfully from control, highlighting the gap between molecular signals and whole-organism outcomes.
SIRT6 is well established in geroscience for its roles in DNA repair, genomic stability, and metabolic regulation. The centenarian-derived SIRT6c variant shows enhanced deacetylase activity. If day 320 data confirm and strengthen the current signals across molecular, structural, and functional domains, SLAB could provide meaningful evidence that aging biology remains modifiable even in older animals — a finding with direct implications for human longevity medicine.
Key Findings
- DNA methylation biological age fell up to 1.08 years in treated dogs vs. 0.07 years in controls at day 182.
- 10 of 12 pDNA-treated beagles showed a biological age reduction on the Horvath dog epigenetic clock.
- Type II muscle fiber preservation and increased regenerative satellite cell density observed in treated animals.
- No adverse safety signals reported; the therapy was well tolerated across all dose groups.
- Primary confirmatory endpoint at day 320 remains pending; current results are not yet statistically significant.
Methodology
This is a news report summarizing interim data from an ongoing randomized, blinded, controlled preclinical trial (n=24 beagles) presented at a conference. Evidence is preliminary — primary endpoints have not yet been reached — and peer-reviewed publication is pending. Conference presentations may reflect selective or early data.
Study Limitations
Results are interim, not peer-reviewed, and drawn from a conference presentation rather than a published study. No between-group differences reached statistical significance at day 182, and functional frailty measures did not separate from controls. Species translation from dogs to humans is uncertain and the primary endpoint data at day 320 are still outstanding.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: